Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

GHK-Cu

Removed from Cat 2

Growth & Recovery · Research peptide (multiple suppliers)

Naturally occurring copper-binding tripeptide researched for wound healing, collagen synthesis, and tissue remodeling. Not FDA-approved for any indication.

About

Mechanism
Naturally occurring copper-binding tripeptide. Stimulates collagen synthesis, promotes wound healing, has anti-inflammatory and antioxidant properties. Activates tissue remodeling genes.
Half-Life
Estimated 1-2 hours
Route
subcutaneous
Frequency
Once daily

Clinical Dosing

1-3 mgonce daily

Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category
Research peptide (removed from FDA Category 2)
Reclassification
removed-from-cat2
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Pickart & Margolina, Oxidative Medicine and Cellular Longevity, 2012

DoseDurationDraw (50 mg vial in 2mL)Notes
1 mgMaintenance0.04 mL (4 units)Standard research dose

Available Vial Sizes

50 mg

50 mg vial

100 mg

100 mg vial

Citations

  1. [1]The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxidative Medicine and Cellular Longevity, 2012, 324832. Link(Reviewed: 2026-04-16)